They will if the generic drug is an opioid that carries the potential for addiction and the new medicine is a non-opioid that poses no such known risk. That’s the opinion of top Vertex ...
The Phase IIa results continue a surge of momentum in a treatment space that last week saw the approval of Vertex’s Journavx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results